BAY 94-9027 Shows Extended Duration in Hemophilia A Patients in Analysis of Trial Data
BAY 94‐9027, an investigational factor VIII replacement therapy being developed by Bayer for severe hemophilia A, is able to stay longer in patients’ blood than other standard therapies, according to a study analyzing data from three…